/
RSS Feed
Big improvements in survival among patients with multiple myeloma were reported at the European Hematology Association annual congress in Barcelona by Greek researchers looking at the past decade of therapy with the novel agents: thalidomide, lenalidomide and bortezomib in the “real world” setting. Professor Evangelos Terpos from the University of Athens discusses his groups findings on bone metabolism under novel agent therapy and assesses the impact of these drugs on survival among patients in Greece.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/100628EvangelosTerposPODCAST.mp3]
